Analyst Ratings January 29, 2026

Truist Reaffirms Buy on Gilead After HIV Franchise Review, Sets $145 Target

Analyst confidence centered on HIV business strength and potential catalysts across oncology and immunology

By Priya Menon GILD
Truist Reaffirms Buy on Gilead After HIV Franchise Review, Sets $145 Target
GILD

Truist Securities has reiterated a Buy rating on Gilead Sciences (NASDAQ:GILD) and held a $145 price target following an in-depth review of the company’s HIV franchise. The firm cited the franchise as the primary driver of Gilead’s modeled fair value, while also pointing to potential upside from oncology, immunology and other pipeline programs. Market data cited in the analysis shows the stock trading near $139.92 with a one-year return of 50.25%.

Key Points

  • Truist Securities reiterates Buy rating on Gilead and keeps a $145 price target after detailed review of its HIV franchise.
  • The HIV portfolio accounts for about 70% of Truist’s modeled fair value and supports significant portions of Gilead’s $29.09 billion revenue and 78.72% gross margin.
  • Additional upside potential noted in oncology and immunology pipelines, with recent commercial and clinical developments—particularly Yeztugo coverage and Trodelvy plus Keytruda results—cited by multiple firms.

Truist Securities has kept a Buy recommendation and a $145.00 price target on shares of Gilead Sciences (NASDAQ:GILD) after conducting proprietary diligence and key opinion leader checks focused on the company’s HIV business. The research note underscores the centrality of that franchise to Gilead’s valuation and highlights additional therapeutic areas that could support sustained growth.

Valuation and market performance

Truist’s $145 target sits close to InvestingPro’s Fair Value estimate and follows an analysis that attributes roughly 70% of Gilead’s modeled fair value to its HIV franchise. The firm’s note reiterates that the HIV portfolio is a major contributor to the company’s top-line and margin profile, within a fiscal framework that includes $29.09 billion in revenue and a gross profit margin of 78.72%.

At the time of the report, the stock was trading at $139.92 and has delivered strong returns over the prior 12 months, with a reported 50.25% gain.

Competitive and script dynamics

Truist framed its conclusions amid what it described as an "intensifying debate" about script trends and the outlook for specific Gilead HIV products, including Yeztugo and Biktarvy, as well as broader competitive pressures across HIV treatment and PrEP markets. The note acknowledges that these market dynamics are under scrutiny but finds the firm’s position durable based on its diligence.

The firm expects Gilead to continue executing on multiple product introductions, naming BIC/LEN among the launches it expects will help sustain the company’s market position. Truist’s assessment suggests that ongoing commercial execution across the HIV portfolio will be critical to maintaining the franchise’s valuation contribution.

Pipeline catalysts and cross-portfolio upside

Beyond HIV, Truist flagged potential catalysts in oncology, immunology and other pipeline areas that could provide additional upside and support what the firm describes as a path to durable multiyear growth. These prospective drivers were highlighted as supplementary to the company’s established HIV revenues rather than replacements.

Recent developments and peer analyst views

The report referenced recent activity around Gilead’s Yeztugo launch and insurance coverage expansion. Truist increased its price target to $145 while maintaining its Buy rating following a pre-report on Yeztugo and reports of expanded payer access. BMO Capital raised its own target to $150, citing momentum in Gilead’s HIV business and noting Yeztugo produced approximately $150 million in fiscal year 2025 sales. The drug’s coverage was noted as exceeding 80% after confirmation of coverage from CVS.

Clinical progress was also cited. Gilead reported that a combination of Trodelvy and Keytruda produced a 35% reduction in the risk of disease progression or death in a trial for metastatic triple-negative breast cancer. Those results, published in The New England Journal of Medicine, showed improved progression-free survival relative to standard care.

Other sell-side activity referenced in the note included Bernstein reiterating an Outperform rating with a $135 price target—calling out the Yeztugo launch as a central growth strategy—and UBS maintaining a Buy rating with a $145 target, highlighting early Yeztugo performance following CVS access.

Conclusion

Truist’s reaffirmation of a Buy rating and a $145 target is rooted in a concentrated view of Gilead’s HIV franchise as the primary driver of value, with additional upside potential from oncology, immunology and other pipeline programs. The firm’s stance reflects optimism about Gilead’s commercial execution on new launches and the accumulation of payer access for key products, while acknowledging debate about script trends and market competition.

Risks

  • Uncertainty around script trends and competitive pressures in HIV and PrEP markets could affect sales momentum and market share in the HIV sector.
  • The company’s outlook depends on continued execution across new product launches such as BIC/LEN; any shortfall in launch performance could weigh on near-term growth.
  • Payer coverage dynamics remain material—while Yeztugo coverage expanded to over 80% after CVS confirmation, changes in insurance access could influence commercial performance.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026